Lenvatinib – 25 mg

Brand:
Cayman
CAS:
417716-92-8
Storage:
-20
UN-No:
Non-Hazardous - /

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively).{32663,32664} It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively).{32663} Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.  

 

Available on backorder

SKU: - Category:

Description

An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα , PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day


Formal name: 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide

Synonyms:  E-7080|ER-203492-00

Molecular weight: 426.9

CAS: 417716-92-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling